anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Season of birth, viral infections, HLA haplogenotypes and non-HLA variants are implicated in the development of celiac disease and celiac disease autoimmunity, suggesting a combined role of genes and environmental exposures. The aim of the study was to further decipher the biological pathways conveying the season of birth effect in celiac disease autoimmunity to gain novel insights into the early pathogenesis of celiac disease. Interactions between season of birth, genetics, and early-life environmental factors on the risk of celiac autoimmunity were investigated in the multicenter TEDDY birth cohort study. Altogether 6523 genetically predisposed children were enrolled to long-term follow-up with prospective sampling and data collection at six research centers in the USA, Germany, Sweden and Finland. Celiac disease autoimmunity was defined as positive tissue transglutaminase antibodies in two consecutive serum samples. There was a significant season of birth effect on the risk of celiac autoimmunity. The effect was dependent on polymorphisms in CD247 gene encoding for CD3ζ chain of TCR-CD3 complex. In particular, children with major alleles for SNP rs864537A > G, in CD247 (AA genotype) had an excess risk of celiac autoimmunity when born March-August as compared to other months. The interaction of CD247 with season of birth on autoimmunity risk was accompanied by interactions with febrile infections between the ages of 3-6 months. Considering the important role of TCR-CD3 complex in the adaptive immune response and our findings here, CD247 variants and their possible effect of subgroups in autoimmunity development could be of interest in the design of future gene-environment studies of celiac disease. ClinicalTrials.gov Identifier: NCT00279318.
The oral LD50 of spironolactone is greater than 1000 mg/kg in mice, rats, and rabbits. The oral LD50 of hydrochlorothiazide is greater than 10 g/kg in both mice and rats.

Acute overdosage of spironolactone may be manifested by drowsiness, mental confusion, maculopapular or erythematous rash, nausea, vomiting, dizziness, or diarrhea. Rarely, instances of hyponatremia, hyperkalemia (less commonly seen with spironolactone and hydrochlorothiazide tablets because the hydrochlorothiazide component tends to produce hypokalemia), or hepatic coma may occur in patients with severe liver disease, but these are unlikely due to acute overdosage.

However, because spironolactone and hydrochlorothiazide tablets contain both spironolactone and hydrochlorothiazide, the toxic effects may be intensified, and signs of thiazide overdosage may be present. These include electrolyte imbalance such as hypokalemia and/or hyponatremia. The potassium-sparing action of spironolactone may predominate and hyperkalemia may occur, especially in patients with impaired renal function. BUN determinations have been reported to rise transiently with hydrochlorothiazide. There may be CNS depression with lethargy or even coma.

Treatment: Induce vomiting or evacuate the stomach by lavage. There is no specific antidote. Treatment is supportive to maintain hydration, electrolyte balance, and vital functions.

Patients who have renal impairment may develop spironolactone-induced hyperkalemia. In such cases, spironolactone and hydrochlorothiazide tablets should be discontinued immediately. With severe hyperkalemia, the clinical situation dictates the procedures to be employed. These include the intravenous administration of calcium chloride solution, sodium bicarbonate solution, and/or the oral or parenteral administration of glucose with a rapid-acting insulin preparation. These are temporary measures to be repeated as required. Cationic exchange resins such as sodium polystyrene sulfonate may be orally or rectally administered. Persistent hyperkalemia may require dialysis.
A portable medication dispenser aids and monitors regimen-conforming use of medications provided in standard as-marketed blister packages. A standard blister package and a separate, disposable sensor sheet are simply and easily loaded into a compact housing containing supervisory electronics, visual indicators, and an audible alarm. The sensor sheet consists of electrical or optical sensing regions corresponding to each individual compartment of the blister package. A compliant, electrically conductive or optical connector in the dispenser housing allows periodic scanning of the sensor sheet circuitry by the control circuitry in the dispenser housing without adding connector components to the low cost, disposable sensor sheet. When a medication is ejected through the backing layer of the standard blister package, an electrical or optical parameter associated with a corresponding region of the sensor sheet is altered, thereby permitting the control circuitry to monitor the dispensing event. Stored patient compliance data may then be reported remotely through an optical or electrical interface between the dispenser and an external system for review by the pharmacist/physician.
PURPOSE:To produce the subject compound useful as treating agent for ovarian cancer, mammary cancer and pulmonary cancer on an industrial scale at a low cost by culturing a cultured cell or cultured tissue of a plant capable of producing a taxane-type diterpene in a medium containing Li ion and recovering the product from the cultured material. CONSTITUTION:A part such as stalk of a planet capable of producing a taxane- type diterpene (e.g. Taxus baccata, a kind of yew tree) is sterilized and placed on a solid medium incorporated with naphthaleneacetic acid and subjected to static culture at 25 deg.C to obtain a callus. The callus is transferred to a well containing a liquid medium, cultured by spinning culture on a rotary shaker and subcultured every 28 days to increase the growth rate of the callus and obtain cultured cells. The cultured cell or cultured tissue is transferred into a well containing a liquid medium incorporated with lithium chloride in an amount to get a lithium ion concentration of >=0.01mM and cultured under shaking at 25 deg.C for 28 days to easily obtain a large amount of taxane-type diterpene (e.g. taxol) useful as a treating agent, etc., such as an agent for the treatment of ovarian cancer, mammary cancer and pulmonary cancer.
ACTOPLUS MET is not recommended for use in pregnancy or for use in pediatric patients.

The initial and maintenance dosing of ACTOPLUS MET should be conservative in patients with advanced age, due to the potential for decreased renal function in this population. Any dosage adjustment should be based on a careful assessment of renal function. Generally, elderly, debilitated, and malnourished patients should not be titrated to the maximum dose of ACTOPLUS MET. Monitoring of renal function is necessary to aid in prevention of metformin-associated lactic acidosis, particularly in the elderly (see WARNINGS, Metformin hydrochloride and PRECAUTIONS, General: Metformin hydrochloride).

Therapy with ACTOPLUS MET should not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT greater than 2.5 times the upper limit of normal) at start of therapy (see PRECAUTIONS, General: Pioglitazone hydrochloride and CLINICAL PHARMACOLOGY, Special Populations, Hepatic Insufficiency). Liver enzyme monitoring is recommended in all patients prior to initiation of therapy with ACTOPLUS MET and periodically thereafter (see PRECAUTIONS, General: Pioglitazone hydrochloride and PRECAUTIONS, Laboratory Tests).
Tubedown-1 (tbdn-1), a protein associated with acetyltransferase activity has been characterized and its cDNA isolated. Tbdn-1 regulates endothelial differentiation through protein acetylation, DNA-binding or by interacting with and/or acetylating other protein targets important for endothelial differentiation. In normal adult eyes, tbdn-1 is expressed highly in the corneal endothelium proper and in the vascular endothelium of the limbus and retina. Tbdn-1 is absent or downregulated in the vascular endothelia of diseased and injured eyes, including eyes from patients with proliferative retinopathies involving neovascularization. Inhibition of tbdn-1 expression in endothelial cells in vitro indicates tbdn-1 acts as an inhibitor of angiogenesis. Thus, high levels of tbdn-1 expression present in normal ocular endothelial cells is associated with suppression of abnormal neovascularization in the eye demonstrating the therapeutic usefulness of tbdn-1 as a regulator of retinal angiogenesis.
BACKGROUND: Poor sleep quality is a serious concern among diabetes mellitus patients, adversely affecting glycemic management and the prognosis of diabetic patients. Therefore, the main aim of this study was to estimate the overall pooled prevalence of poor sleep quality and its associated factors among diabetic patients in Sub-Saharan Africa.
METHODS: Several search databases were employed to retrieve the eligible studies. A standardized data extraction format was used to extract the data, and the analysis was conducted using STATA version 14. To determine heterogeneity, the I2 test was conducted, and both the funnel plot and Egger's regression test were used to assess the publication bias. A random effects model meta-analysis was performed to estimate the overall prevalence and associated factors of poor sleep quality.
RESULTS: In the current meta-analysis, a total of 11 studies with 3,766 study participants were included. The overall pooled prevalence of poor sleep quality among diabetic patients was 53.22% (95% CI: 36.26, 70.19). Poor sleep quality was significantly associated with longer duration of diabetes (OR = 2.94, 95% CI: 1.85, 4.67), poor glycemic control (OR = 2.24, 95% CI: 1.51, 3.32), depression (OR = 4.09, 95% CI: 2.07, 8.05) and comorbidity (OR = 1.94, 95% CI: 1.31, 2.88).
CONCLUSION: In this study, more than half of diabetic patients in Sub-Saharan Africa had poor sleep quality. Therefore, healthcare providers should give more attention to sleep disorders when screening diabetic patients to improve their poor sleep quality.
Disclosed herein is a system and methods for determining the alleles, neoantigens, and vaccine composition as determined on the basis of an individual’s tumor mutations. Also disclosed are systems and methods for obtaining high quality sequencing data from a tumor. Further, described herein are systems and methods for identifying somatic changes in polymorphic genome data. Further, described herein are systems and methods for selecting a subset of patients for treatment. A utility score indicating an estimated number of neoantigens presented on the surface of tumor cells is determined for each patient based on one or more neoantigen candidates identified for the patient. The subset of patients are selected based on the determined utility scores. The selected subset of patients can receive treatment, such as neoantigen vaccines or checkpoint inhibitor therapy. Finally, described herein are unique cancer vaccines.
FIELD: medicine.SUBSTANCE: implant for bone tissue regeneration consists of composite microparticles characterized by porous structure with pore size from 10 to 85 mcm, content of silk fibroin from 65 to 75 wt. %, content of gelatine from 25 to 35 wt. %, as well as Young's modulus of compression in dehydrated state 83 ± 1 MPa, in wet - 590 ± 60 kPa. Method of implant production includes the following stages: preparing an aqueous solution of fibroin, preparing an aqueous solution of gelatine, forming a composite scaffold, cryomilling the scaffold obtained at the step of forming a composite scaffold, and deposition of composite microparticles obtained at step of cryophasing scaffold. Preparation of water solution of silk fibroin is performed by dissolving fibroin in amount of 100–150 mg/ml in CaClmixture: CHOH: HO in molar ratio of components of mixture of 1:2:8 for 5–7 hours while heating to 70 °C±5 °C and subsequent dialysis against water, centrifugation at 13,400 g for 10 minutes and bringing the obtained solution with water to concentration of 20–30 mg/ml. Preparation of aqueous solution of gelatine is carried out by dissolution of dry gelatine in water at rate of 20–30 mg/ml. Composite scaffold formation is performed by freezing for 6–8 days at temperature - (18–25) °C a mixture of solutions obtained at the steps of preparing an aqueous solution of silk fibroin and preparing an aqueous solution of gelatine in volume ratio of 7:3 and 0.8–1.2 vol. % dimethylsulphoxide (DMSO) with subsequent defrosting and treatment with 96 % ethanol, which provides formation β-flat structure, then scaffolds are frozen in distilled water. Creeping of scaffold obtained at the stage of composite scaffold formation is carried out in 70 % ethanol using a dispersant, followed by sorting obtained scaffold fragments to obtain composite microparticles with size of 100–250 mcm. Deposition of composite microparticles obtained at cryofilling of scaffold is suspended from suspension in 70 % ethanol at 13,000–18,000 g for 30–40 minutes followed by drying at 50–55°C for at least 2 days to form an implant for bone tissue regeneration.EFFECT: inventions provide simplification of technology of implant obtaining combined with improvement of mechanical characteristics of obtained implant, in particular of Young's modulus when measuring for compression, improvement of its osteinductive properties that promotes faster healing and regeneration of bone tissue.3 cl, 6 dwg
Introduction. Data on the frequency of enteric adenoviruses, sapoviruses, and astroviruses in cases of sporadic acute gastroenteritis in Argentina are scarce. Methods. Descriptive design of a selection of fecal samples of children with diarrhea younger than 5 years referred between 2010 and 2021, with a previous negative result for rotavirus and norovirus. The presence of enteric adenovirus, sapovirus, and astrovirus was tested by molecular methods, with subsequent genotyping of positive samples. Results. At least 1 of the tested viruses was detected in 226 (39.4%) of the 574 selected samples. Specifically, adenovirus, sapovirus, and astrovirus were detected in 30.7%, 5.6%, and 3.1% of the samples, respectively. The most frequent viruses detected were adenovirus 41, sapoviruses GI.1 and GI.2, and astrovirus 1. Non-classic astroviruses were detected in 2 samples. Conclusions. Despite being less frequent, these enteropathogens are responsible for a large number of sporadic diarrhea events. Therefore, their study and surveillance contribute significantly to reduce the gap of undiagnosed cases.
The study will use a three-pronged approach: year-long weekly Financial and Health Diaries, Baseline and Endline surveys, and qualitative interviews. The Diaries and the Surveys will be carried out in two Counties, Kakamega and Kisumu (Kenya). The qualitative interviews will be carried out in the two counties and in Nairobi as an additional county. The study will use a cluster randomized control trial design in Kakamega to evaluate the impact of I-PUSH program. In Kisumu, selected households will be followed-up to capture the health-seeking behavior, health insurance, and health expenditure pattern of households over time. The study will be initially for 17 months and will continue for three years subject to additional funding.
Patients will undergo preoperative lymphoscintigraphy in the nuclear medicine department to access axillary and extra-axillary sites of localization. Intraoperatively, patients will also be injected with approximately 4 to 5 mL of 1% isosulfan blue dye (by intradermal, intraparenchymal, or subareolar route). Patients will undergo intraoperative identification and biopsy of all SLN candidates. A confirmatory axillary lymph node dissection will then be performed on all patients.
We will perform a single site clinical trial in obese women not at risk of pregnancy aged 18 to 40. We will screen to enroll and complete 22 participants. Each participant after signing an Informed Consent and meeting all inclusion and exclusion criteria will be enrolled on menstrual day 9-10 of a subsequent menstrual cycle following a negative urine pregnancy test. Each participant will be asked to collect a first morning voided urine sample beginning on menstrual day 9 and completing 15 days later on menstrual day 24. The participant will undergo a transvaginal ultrasound on menstrual days 9-10, 12, 13 and day 14 to determine ovarian follicle diameters in two planes frontal and sagittal using transvaginal ultrasound. When the largest follicle diameter is 17±1.0 millimeters (mm) the participant will be given the intervention: placebo in the 1st cycle and levonorgestrel plus meloxicam in the 2nd cycle followed by a second dose of each intervention 48 hours later. The ovarian follicle dimension of 17 mm occurs in the middle of the woman's window of fertility which is the four days preceding plus the day of ovulation. We anticipate that ovulation will take place within 3 days after the first placebo dose in 90% of the participants and will be delayed ≥7 days following the first dose of levonorgestrel plus meloxicam in ≥80% of the participants. The primary outcome is the delay in days from the first dose to evidence of ovarian corpus luteum formation which follows ovulation. All urine samples from the same participant will be analyzed in one assay for estrogen and progesterone metabolites to reduce inter-assay variability. The primary outcome will be delay of ovulation based on changes in the ratio of the urinary metabolites in obese women between placebo and active treatment. Secondary outcomes (exploratory) are a) safety parameters vital signs consisting of blood pressure and pulse obtained at each visit, b) adverse events, unscheduled bleeding, and changes in menstrual bleeding captured by the participant using a daily diary card. She will be instructed to write down any symptoms or problem along with medication taken both study drug and any other medication. Any treatment adverse event considered to be serious will be reported to the local institutional review board and the Food and Drug Administrating within 72 hours of our being made aware of the problem. The occurrence, percentage, and relationship to study drug of minor and moderate adverse events will be noted and categorized using Medical Dictionary for Regulatory Activates (MedRA) adverse event classification and listed in all reports and publications.

Each participant will be involved for a study period of approximately 2.5 months or 75 days. Each participant will undergo a complete history and physical evaluation at entry and a brief interim history and physical evaluation at exit with height and weight at entry. Mean and standard deviation of all vital signs before and after treatment, menstrual bleeding changes and treatment emergent adverse events will be compiled and listed in all reports and publications.
PURPOSE:To obtain a monoclonal antibody belonging to IgG1 class and capable of correctly discriminating cancer diseases from non-cancer ones. CONSTITUTION:Spleen cells of a mouse spleen immunized with human thymic carcinoma cells (e.g. cultured cell A-549) are fused with cancer cells, e.g. myeloma cells having self-reproduction ability and the resultant fused androblastomas are screened to obtain a fused androblastoma 1G12 strain capable of producing a monoclonal antibody having various specificities against various cultured cell lines. The resultant screened fused androblastoma is subsequently administrated into, e.g. a BALB/C mouse abdominal cavity dosed with pristane, thus obtaining abdominal dropsy containing a large amount of the objective antibody. The resultant abdominal dropsy is collected and purified to obtain the objective antibody.
Delirium is a costly and devastating illness affecting older patients in the hospital. Its prevalence increases as patients get older and sicker. There is scientific evidence that delirium affects cognitive function for a prolonged period of time and in many cases irreversibly. The economic burden on health care and emotional burden on the caregivers of patients with delirium is tremendous. We think that our study may contribute to developing prevention strategies for delirium in the hospital. We propose genetic testing of older patients to determine their ability to metabolize commonly used medications in the hospital. This will give medical professionals and pharmacists an ability to adjust dosages of medications based on the patient's genetic profile.
Collagenous material is converted into an irreversably cross-linked thermostable polymer by irradiation e.g. in aqueous solution or dispersion at pH 2-10, in the presence of a photosensitive derivative of isoalloxazine which may be denoted generally as 6,7(R,R1)-9(11-X)-isoalloxazines wherein R and R1 are interchangeably hydrogen atoms or C1-6 alkyl groups and X is ribityl, phosphoribityl or a mono- or poly-acetoribityl or malonyl groups and the water-soluble salts and dinucleotide derivatives thereof.  Riboflavin (preferred) and riboflavin-5-phosphate are specified.  Specified collagenous material is native collagen e.g. tendon, hide, gut and ichthycoll which may be previously treated e.g. by enzymatic digestion to remove effete matter, partially degraded collagen e.g. gelatin, native collagen in which the available side groups are esterified with an alkanol of 1-20 carbon atoms and extracts of collagenous material obtained by extraction with an alkali-metal halide solution, purification and concentration.ALSO:Fibres, films and sponges for surgical use and matrices for tissue culture are prepared from a polymerized acid dispersion of a collagenous material the polymerization being brought about by irradiation in the presence of a photosensitive isoallexazine photocatalyst (see Group IV (b)). The sponges may be impregnated with drugs, e.g. hemostatic agents such as heparin, hormones, antibiotics, e.g. penicillin and tetracyclines or wound-healing accelerators, e.g. Vitamin C, Vitamin A, urea or streptogenesis.
<P>PROBLEM TO BE SOLVED: To provide a liquid deodorant which can be easily used by a means such as a spray, has high deodorizing effect, and can be safely used for an organism such as a pet animal and the human body.  <P>SOLUTION: This liquid deodorant contains myrrh extract which is obtained by extracting from mirrh resin with ethanol, and water. The liquid deodorant can be easily and safely used by a means such as a spray even for an organism such as a pet animal and the human body, causes no problem for environmental pollution, and has excellent deodorizing effect against various kinds of malodorous components such as ammonia, hydrogen sulfide, acetic acid and formaldehyde. Since the liquid deodorant contains extract of mirrh with action as an antiseptic, the liquid deodorant can be preserved with stable quality without using a synthetic preservative. A method for manufacturing the liquid deodorant with excellent characteristics is also provided.  <P>COPYRIGHT: (C)2004,JPO